Roche Reports Launch of First CDx VENTANA PD-L1 (SP142) Assay Identifying TNBC Patients Eligible for Treatment with Tecentriq (atezolizumab)

 Roche Reports Launch of First CDx VENTANA PD-L1 (SP142) Assay Identifying TNBC Patients Eligible for Treatment with Tecentriq (atezolizumab)

The European Commission Signs an Agreement with Roche and Merck to Supply their COVID-19 Therapies in EU

Shots:

  • The launch of VENTANA PD-L1 (SP142) follows the US FDA’s approval in Mar’2019, as the first CDx assay involved in identifying triple-negative breast cancer (TNBC) patients associated with 3 proteins estrogen receptor, progesterone receptor and HER2/neu eligible for treatment with Tecentriq combination
  • The assay is developed for the enhancement of visual contrast of tumor-infiltrating immune cell staining and was also used in enrolling the patients in IMpassion 130 trial assessing Tecentriq and evaluated patients with PD-L1 biomarker using immune cell screening and scoring in tumor cells
  • The VENTANA PD-L1 (SP142) Assay is an automated BenchMark IHC/ISH series instrument utilizes OptiView DAB IHC Detection Kit with OptiView Amplification Kit and is involved in performing staining of tumor cells and immune cells, also FDA approved and CE marked assay  

Click here to read full press release/ article | Ref: Roche | Image: Behance

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post